« Return to News | Technology Solutions

Almac launches COMPASS platform to improve clinical trial management

Wednesday, December 7, 2011 10:21 AM

Almac has launched of its new forecasting platform, COMPASS, which has been designed to improve the accuracy and efficiency of the supply inventory process during clinical studies. COMPASS provides benefits to clients by allowing the Supply Chain Manager to proactively direct the entire clinical supply chain, ultimately saving money that is often lost through inaccurate forecasting or overproduction of supplies.  

COMPASS allows the Supply Chain Manager to produce material forecasts for bulk product, finished goods, and packaging components. Typically a number of forecast scenarios are produced upfront using available data such as patient recruitment projections and protocol information. Clients can then select the most appropriate model to proceed with. 

COMPASS can update the material forecast throughout the maintenance phase of the trial based on actual patient usage data. This allows the Supply Chain Manager to then review the system outputs and evaluate production and distribution strategies to ensure they are inline with the forecast. 

COMPASS will be offered as part of Almac’s Supply Chain Management services at all sites and for customers of all sizes.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.